|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
|
US6761888B1
(en)
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
|
US7588766B1
(en)
|
2000-05-26 |
2009-09-15 |
Elan Pharma International Limited |
Treatment of amyloidogenic disease
|
|
PE20020574A1
(es)
|
2000-12-06 |
2002-07-02 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido amiloideo beta
|
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
|
US7981420B2
(en)
|
2000-12-22 |
2011-07-19 |
Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. |
Therapeutic use of antibodies directed against repulsive guidance molecule (RGM)
|
|
WO2003015691A2
(en)
*
|
2001-08-17 |
2003-02-27 |
Eli Lilly And Company |
RAPID IMPROVEMENT OF COGNITION IN CONDITIONS RELATED TO A$g(b)
|
|
US7771722B2
(en)
*
|
2001-08-17 |
2010-08-10 |
Eli Lilly And Company |
Assay method for alzheimer's disease
|
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
|
EP1596809B1
(en)
*
|
2003-02-10 |
2010-05-26 |
Applied Molecular Evolution, Inc. |
Abeta binding molecules
|
|
TWI374893B
(en)
|
2003-05-30 |
2012-10-21 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
|
US20110142858A1
(en)
*
|
2004-06-07 |
2011-06-16 |
Ramot At Tel Aviv University Ltd. |
Method of Passsive Immunization Against Disease or Disorder Charcterized by Amyloid Aggregation with Diminished Risk of Neuroinflammation
|
|
WO2006066089A1
(en)
|
2004-12-15 |
2006-06-22 |
Neuralab Limited |
Humanized amyloid beta antibodies for use in improving cognition
|
|
TW200636066A
(en)
|
2004-12-15 |
2006-10-16 |
Elan Pharm Inc |
Humanized antibodies that recognize beta amyloid peptide
|
|
TW200635608A
(en)
*
|
2004-12-15 |
2006-10-16 |
Neuralab Ltd |
Aβ antibodies for use in improving cognition
|
|
GT200600031A
(es)
*
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
|
CN101213211A
(zh)
|
2005-06-17 |
2008-07-02 |
惠氏公司 |
纯化含Fc区蛋白的方法
|
|
CN103145840A
(zh)
|
2005-06-30 |
2013-06-12 |
Abbvie公司 |
Il-12/p40结合蛋白
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
EP2500358A3
(en)
|
2005-08-19 |
2012-10-17 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
EP2520588A1
(en)
|
2005-08-19 |
2012-11-07 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
GB0519398D0
(en)
*
|
2005-09-23 |
2005-11-02 |
Antisoma Plc |
Biological materials and uses thereof
|
|
WO2007039256A2
(de)
|
2005-09-30 |
2007-04-12 |
Abbott Gmbh & Co. Kg |
Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
|
|
RU2442793C2
(ru)
|
2005-11-30 |
2012-02-20 |
Эбботт Лэборетриз |
АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
|
|
CN101506236B
(zh)
*
|
2005-11-30 |
2012-12-12 |
雅培制药有限公司 |
抗淀粉样β蛋白的单克隆抗体及其用途
|
|
AU2013200177B2
(en)
*
|
2005-11-30 |
2014-10-02 |
Abbvie Deutschland Gmbh & Co Kg |
Monoclonal antibodies against amyloid beta protein and uses thereof
|
|
RU2551782C2
(ru)
|
2005-12-12 |
2015-05-27 |
Ац Иммуне Са |
Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами
|
|
CN101351476B
(zh)
*
|
2005-12-12 |
2013-04-03 |
豪夫迈·罗氏有限公司 |
抗体可变区的糖基化
|
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
|
TWI551607B
(zh)
|
2006-07-14 |
2016-10-01 |
Ａｃ免疫公司 |
人類化抗體
|
|
JP2010502224A
(ja)
|
2006-09-08 |
2010-01-28 |
アボット・ラボラトリーズ |
インターロイキン１３結合タンパク質
|
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
|
AU2008206555B2
(en)
|
2007-01-18 |
2013-07-04 |
Eli Lilly And Company |
Pegylated Abeta Fab
|
|
CA2676715A1
(en)
|
2007-02-12 |
2008-08-21 |
Merck & Co., Inc. |
Piperazine derivatives for treatment of ad and related conditions
|
|
EP2124952A2
(en)
|
2007-02-27 |
2009-12-02 |
Abbott GmbH & Co. KG |
Method for the treatment of amyloidoses
|
|
EP2481408A3
(en)
|
2007-03-01 |
2013-01-09 |
Probiodrug AG |
New use of glutaminyl cyclase inhibitors
|
|
WO2008128985A1
(en)
|
2007-04-18 |
2008-10-30 |
Probiodrug Ag |
Thiourea derivatives as glutaminyl cyclase inhibitors
|
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
|
US7931899B2
(en)
|
2007-05-14 |
2011-04-26 |
Medtronic, Inc |
Humanized anti-amyloid beta antibodies
|
|
US8323654B2
(en)
|
2007-05-14 |
2012-12-04 |
Medtronic, Inc. |
Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
|
|
EP2170389B1
(en)
*
|
2007-06-12 |
2014-10-29 |
AC Immune S.A. |
Humanized antibodies to amyloid beta
|
|
US8048420B2
(en)
|
2007-06-12 |
2011-11-01 |
Ac Immune S.A. |
Monoclonal antibody
|
|
US8613923B2
(en)
|
2007-06-12 |
2013-12-24 |
Ac Immune S.A. |
Monoclonal antibody
|
|
ES2498040T3
(es)
|
2007-07-27 |
2014-09-24 |
Janssen Alzheimer Immunotherapy |
Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
|
|
RU2482876C2
(ru)
|
2007-10-05 |
2013-05-27 |
Дженентек, Инк. |
Применение антитела против амилоида-бета при глазных заболеваниях
|
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
EP2222700A2
(en)
*
|
2007-11-27 |
2010-09-01 |
Medtronic, Inc. |
Humanized anti-amyloid beta antibodies
|
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
|
JP5646457B2
(ja)
|
2008-04-29 |
2014-12-24 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリン及びその使用
|
|
KR101649189B1
(ko)
|
2008-05-09 |
2016-08-18 |
애브비 인코포레이티드 |
최종 당화 산물의 수용체(ｒａｇｅ)에 대한 항체 및 이의 용도
|
|
JP5723769B2
(ja)
|
2008-06-03 |
2015-05-27 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリン及びその使用
|
|
NZ589434A
(en)
|
2008-06-03 |
2012-11-30 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
MX2010014574A
(es)
|
2008-07-08 |
2011-04-27 |
Abbott Lab |
Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
|
|
WO2010006059A1
(en)
|
2008-07-08 |
2010-01-14 |
Abbott Laboratories |
Prostaglandin e2 binding proteins and uses thereof
|
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
|
US8614297B2
(en)
|
2008-12-22 |
2013-12-24 |
Hoffmann-La Roche Inc. |
Anti-idiotype antibody against an antibody against the amyloid β peptide
|
|
US8030026B2
(en)
|
2009-02-24 |
2011-10-04 |
Abbott Laboratories |
Antibodies to troponin I and methods of use thereof
|
|
KR101579771B1
(ko)
|
2009-03-05 |
2015-12-28 |
애브비 인코포레이티드 |
Ｉｌ-17 결합 단백질
|
|
US8283162B2
(en)
|
2009-03-10 |
2012-10-09 |
Abbott Laboratories |
Antibodies relating to PIVKAII and uses thereof
|
|
SG178602A1
(en)
|
2009-09-01 |
2012-04-27 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
CA2772488C
(en)
|
2009-09-11 |
2018-04-17 |
Probiodrug Ag |
Heterocyclic derivatives as inhibitors of glutaminyl cyclase
|
|
BR112012008833A2
(pt)
|
2009-10-15 |
2015-09-08 |
Abbott Lab |
imunoglobulinas de dominio variavel duplo e usos das mesmas
|
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
US8420083B2
(en)
|
2009-10-31 |
2013-04-16 |
Abbvie Inc. |
Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
|
|
BR112012013734A2
(pt)
|
2009-12-08 |
2017-01-10 |
Abbott Gmbh & Co Kg |
anticorpos monoclonais contra a proteína rgm a para uso no tratamento da degeneração da camada de fibras nervosas da retina.
|
|
JP6026284B2
(ja)
|
2010-03-03 |
2016-11-16 |
プロビオドルグ エージー |
グルタミニルシクラーゼの阻害剤
|
|
NZ602312A
(en)
|
2010-03-10 |
2014-02-28 |
Probiodrug Ag |
Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
|
|
US8987419B2
(en)
|
2010-04-15 |
2015-03-24 |
AbbVie Deutschland GmbH & Co. KG |
Amyloid-beta binding proteins
|
|
JP5945532B2
(ja)
|
2010-04-21 |
2016-07-05 |
プロビオドルグ エージー |
グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
|
|
PL2571532T3
(pl)
|
2010-05-14 |
2017-10-31 |
Abbvie Inc |
Białka wiążące IL-1
|
|
WO2012006500A2
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
US9120862B2
(en)
|
2010-07-26 |
2015-09-01 |
Abbott Laboratories |
Antibodies relating to PIVKA-II and uses thereof
|
|
CN103179981B
(zh)
|
2010-07-30 |
2017-02-08 |
Ac免疫有限公司 |
安全和功能性的人源化抗β‑淀粉样蛋白抗体
|
|
SG188190A1
(en)
|
2010-08-03 |
2013-04-30 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
CN103119064B
(zh)
|
2010-08-10 |
2018-09-04 |
葛莱高托普有限公司 |
Fab糖基化抗体
|
|
CN103298833B
(zh)
|
2010-08-14 |
2015-12-16 |
Abbvie公司 |
β淀粉样蛋白结合蛋白
|
|
JP2013539364A
(ja)
|
2010-08-26 |
2013-10-24 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリンおよびその使用
|
|
SG10201604699VA
(en)
|
2010-12-21 |
2016-07-28 |
Abbvie Inc |
Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
|
|
EP2686313B1
(en)
|
2011-03-16 |
2016-02-03 |
Probiodrug AG |
Benzimidazole derivatives as inhibitors of glutaminyl cyclase
|
|
CA2830503A1
(en)
|
2011-03-17 |
2012-09-20 |
Minerva Biotechnologies Corporation |
Method for making pluripotent stem cells
|
|
ES2602794T3
(es)
|
2011-03-31 |
2017-02-22 |
Pfizer Inc |
Piridinonas bicíclicas novedosas
|
|
WO2012172449A1
(en)
|
2011-06-13 |
2012-12-20 |
Pfizer Inc. |
Lactams as beta secretase inhibitors
|
|
CN103857411A
(zh)
|
2011-07-13 |
2014-06-11 |
阿布维公司 |
使用抗il-13抗体治疗哮喘的方法和组合物
|
|
ES2605565T3
(es)
|
2011-08-31 |
2017-03-15 |
Pfizer Inc |
Compuestos de hexahidropirano [3,4-D][1,3]tiazin-2-amina
|
|
SG11201401791WA
(en)
|
2011-10-24 |
2014-08-28 |
Abbvie Inc |
Immunobinders directed against sclerostin
|
|
US9120870B2
(en)
|
2011-12-30 |
2015-09-01 |
Abbvie Inc. |
Dual specific binding proteins directed against IL-13 and IL-17
|
|
SG11201404263TA
(en)
|
2012-01-27 |
2014-08-28 |
Abbvie Deutschland |
Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
|
|
ES2585262T3
(es)
|
2012-05-04 |
2016-10-04 |
Pfizer Inc |
Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2
|
|
KR20150027267A
(ko)
|
2012-06-29 |
2015-03-11 |
화이자 인코포레이티드 |
LRRK2 억제제로서의 4-(치환된-아미노)-7H-피롤로[2,3-d]피리미딘
|
|
WO2014011955A2
(en)
|
2012-07-12 |
2014-01-16 |
Abbvie, Inc. |
Il-1 binding proteins
|
|
JP2012233002A
(ja)
*
|
2012-08-03 |
2012-11-29 |
Janssen Alzheimer Immunotherapy |
認知の改善における使用のためのアミロイドβ抗体
|
|
WO2014045162A1
(en)
|
2012-09-20 |
2014-03-27 |
Pfizer Inc. |
ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-ANIME COMPOUNDS
|
|
UA110688C2
(uk)
|
2012-09-21 |
2016-01-25 |
Пфайзер Інк. |
Біциклічні піридинони
|
|
MY171664A
(en)
|
2012-11-01 |
2019-10-22 |
Abbvie Inc |
Anti-dll4/vegf dual variable domain immunoglobulins and uses thereof
|
|
EP2931731A1
(en)
|
2012-12-11 |
2015-10-21 |
Pfizer Inc. |
Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
|
|
US9403846B2
(en)
|
2012-12-19 |
2016-08-02 |
Pfizer Inc. |
Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
|
|
US9550986B2
(en)
|
2012-12-21 |
2017-01-24 |
Abbvie Inc. |
High-throughput antibody humanization
|
|
MX2015008446A
(es)
|
2012-12-28 |
2016-10-26 |
Abbvie Inc |
Composiciones de proteinas de union multivalentes.
|
|
US9458244B2
(en)
|
2012-12-28 |
2016-10-04 |
Abbvie Inc. |
Single chain multivalent binding protein compositions and methods
|
|
EP2948177A1
(en)
|
2013-01-22 |
2015-12-02 |
AbbVie Inc. |
Methods for optimizing domain stability of binding proteins
|
|
WO2014125394A1
(en)
|
2013-02-13 |
2014-08-21 |
Pfizer Inc. |
HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3] THIAZIN-2-AMINE COMPOUNDS
|
|
US9233981B1
(en)
|
2013-02-15 |
2016-01-12 |
Pfizer Inc. |
Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
|
|
KR20150119370A
(ko)
|
2013-02-19 |
2015-10-23 |
화이자 인코포레이티드 |
Cns 장애 및 다른 장애의 치료를 위한 pde4 동종효소의 억제제로서의 아자벤즈이미다졸 화합물
|
|
CN105228649B
(zh)
|
2013-03-14 |
2019-01-18 |
雅培制药有限公司 |
Hcv抗原-抗体组合测定和方法以及用在其中的组合物
|
|
CA2906417C
(en)
|
2013-03-14 |
2022-06-21 |
Robert Ziemann |
Hcv core lipid binding domain monoclonal antibodies
|
|
JP2016512241A
(ja)
|
2013-03-14 |
2016-04-25 |
アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ |
改良された抗体検出のためのｈｃｖｎｓ３組換え抗原およびこの突然変異体
|
|
AU2014227732A1
(en)
|
2013-03-15 |
2015-09-17 |
Abbvie Inc. |
Dual specific binding proteins directed against IL-1 beta and IL-17
|
|
PH12021550015A1
(en)
|
2013-05-20 |
2022-05-11 |
Genentech Inc |
Anti-transferrin receptor antibodies and methods of use
|
|
CA2925743C
(en)
|
2013-10-04 |
2018-03-06 |
Pfizer Inc. |
Novel bicyclic pyridinones as gamma-secretase modulators
|
|
US9695171B2
(en)
|
2013-12-17 |
2017-07-04 |
Pfizer Inc. |
3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
|
|
CA2942101A1
(en)
|
2014-03-21 |
2015-09-24 |
Abbvie Inc. |
Anti-egfr antibodies and antibody drug conjugates
|
|
EP3126361B1
(en)
|
2014-04-01 |
2019-11-06 |
Pfizer Inc |
Chromene and 1,1a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators
|
|
AP2016009493A0
(en)
|
2014-04-10 |
2016-10-31 |
Pfizer |
2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
|
|
WO2015165961A1
(en)
|
2014-04-29 |
2015-11-05 |
Affiris Ag |
Treatment and prevention of alzheimer's disease (ad)
|
|
EP3172210B1
(en)
|
2014-07-24 |
2020-01-15 |
Pfizer Inc |
Pyrazolopyrimidine compounds
|
|
WO2016020786A1
(en)
|
2014-08-06 |
2016-02-11 |
Pfizer Inc. |
Imidazopyridazine compounds
|
|
CN107001473B
(zh)
|
2014-11-19 |
2021-07-09 |
豪夫迈·罗氏有限公司 |
抗-运铁蛋白受体抗体及使用方法
|
|
JP6993228B2
(ja)
|
2014-11-19 |
2022-03-03 |
ジェネンテック， インコーポレイテッド |
抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
|
|
CA2966365A1
(en)
|
2014-12-10 |
2016-06-16 |
Genentech, Inc. |
Blood brain barrier receptor antibodies and methods of use
|
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
|
MX368391B
(es)
|
2015-02-03 |
2019-09-30 |
Pfizer |
Ciclopropabenzofuranil-piridopirazindionas novedosas.
|
|
WO2016160976A2
(en)
|
2015-03-30 |
2016-10-06 |
Abbvie Inc. |
Monovalent tnf binding proteins
|
|
HUE048284T2
(hu)
|
2015-05-29 |
2020-07-28 |
Abbvie Inc |
Anti-CD40 antitestek és alkalmazásuk
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
HUE051898T2
(hu)
|
2015-06-17 |
2021-03-29 |
Pfizer |
Triciklusos vegyületek és alkalmazásuk foszfodiészteráz inhibitorokként
|
|
IL302486A
(en)
|
2015-06-24 |
2023-06-01 |
Hoffmann La Roche |
Antibodies against the transnephrine receptor with adapted affinity
|
|
JP6873980B2
(ja)
|
2015-09-14 |
2021-05-19 |
ファイザー・インク |
ＬＲＲＫ２阻害薬としての新規のイミダゾ［４，５−ｃ］キノリンおよびイミダゾ［４，５−ｃ］［１，５］ナフチリジン誘導体
|
|
WO2017051303A1
(en)
|
2015-09-24 |
2017-03-30 |
Pfizer Inc. |
Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
|
|
EP3353174A1
(en)
|
2015-09-24 |
2018-08-01 |
Pfizer Inc |
N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl]amides useful as bace inhibitors
|
|
AU2016325665A1
(en)
|
2015-09-24 |
2018-03-08 |
Pfizer Inc. |
N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
|
|
CN114057885A
(zh)
|
2015-10-02 |
2022-02-18 |
豪夫迈·罗氏有限公司 |
双特异性抗人cd20/人转铁蛋白受体抗体及使用方法
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
NZ743881A
(en)
|
2016-02-06 |
2023-11-24 |
Epimab Biotherapeutics Inc |
Fabs-in-tandem immunoglobulin and uses thereof
|
|
PT3419979T
(pt)
|
2016-02-23 |
2020-03-26 |
Pfizer |
Compostos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida
|
|
EP3468598A1
(en)
|
2016-06-08 |
2019-04-17 |
AbbVie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
|
RU2018147224A
(ru)
|
2016-06-08 |
2020-07-14 |
Эббви Инк. |
Конъюгаты антитела к egfr и лекарственного средства
|
|
BR112018075649A2
(pt)
|
2016-06-08 |
2019-04-09 |
Abbvie Inc. |
anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo
|
|
WO2017214462A2
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
|
EP3468993A1
(en)
|
2016-06-08 |
2019-04-17 |
AbbVie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
|
BR112018075645A2
(pt)
|
2016-06-08 |
2019-04-09 |
Abbvie Inc. |
conjugados de anticorpo fármaco anti-egfr
|
|
IL300274A
(en)
|
2016-06-08 |
2023-04-01 |
Abbvie Inc |
Antibodies against B7–H3 and conjugates of drug and antibody
|
|
JP2019522643A
(ja)
|
2016-06-08 |
2019-08-15 |
アッヴィ・インコーポレイテッド |
抗ｃｄ９８抗体及び抗体薬物コンジュゲート
|
|
JP2019521114A
(ja)
|
2016-06-08 |
2019-07-25 |
アッヴィ・インコーポレイテッド |
抗ｅｇｆｒ抗体薬物コンジュゲート
|
|
MX386258B
(es)
|
2016-07-01 |
2025-03-18 |
Pfizer |
Derivados de 5,7-dihidro-pirrolo-piridina para tratar enfermedades neurologicas y neurodegenerativas
|
|
WO2018035084A1
(en)
|
2016-08-16 |
2018-02-22 |
Epimab Biotherapeutics, Inc. |
Monovalent asymmetric tandem fab bispecific antibodies
|
|
EP3544628A4
(en)
|
2016-11-23 |
2020-11-18 |
Immunoah Therapeutics, Inc. |
4-1BB BINDING PROTEINS AND THEIR USES
|
|
CN118562004A
(zh)
|
2016-12-16 |
2024-08-30 |
蓝鳍生物医药公司 |
抗-含cub结构域蛋白1(cdcp1)抗体、抗体药物缀合物及其使用方法
|
|
SG11201908322WA
(en)
|
2017-03-10 |
2019-10-30 |
Pfizer |
Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
|
|
AU2018230109B2
(en)
|
2017-03-10 |
2022-05-12 |
Pfizer Inc. |
Cyclic substituted imidazo[4,5-c]quinoline derivatives
|
|
CA3064697A1
(en)
|
2017-04-19 |
2018-10-25 |
Bluefin Biomedicine, Inc. |
Anti-vtcn1 antibodies and antibody drug conjugates
|
|
CN110997693A
(zh)
|
2017-06-07 |
2020-04-10 |
阿德克斯公司 |
τ聚集抑制剂
|
|
CN118994394A
(zh)
|
2017-06-12 |
2024-11-22 |
蓝鳍生物医药公司 |
抗-il1rap抗体和抗体药物缀合物
|
|
KR20200013783A
(ko)
|
2017-06-22 |
2020-02-07 |
화이자 인코포레이티드 |
디히드로-피롤로-피리딘 유도체
|
|
EP3574020B1
(en)
|
2017-07-18 |
2024-05-15 |
The University of British Columbia |
Antibodies to amyloid beta
|
|
EP3668886A2
(en)
|
2017-08-18 |
2020-06-24 |
Adrx, Inc. |
Tau aggregation peptide inhibitors
|
|
ES2812698T3
(es)
|
2017-09-29 |
2021-03-18 |
Probiodrug Ag |
Inhibidores de glutaminil ciclasa
|
|
HUE061533T2
(hu)
|
2018-03-23 |
2023-07-28 |
Pfizer |
Piperazin azaspiro származékok
|
|
MX2020011588A
(es)
|
2018-05-03 |
2020-12-07 |
Shanghai Epimab Biotherapeutics Co Ltd |
Anticuerpos de alta afinidad a pd-1 y lag-3 y proteinas de union bispecificas preparadas a partir de las mismas.
|
|
HUE067382T2
(hu)
|
2018-05-18 |
2024-10-28 |
Daiichi Sankyo Co Ltd |
Anti-MUC1-exatecan antitest-hatóanyag konjugátum
|
|
EP3819311A4
(en)
|
2018-07-17 |
2022-08-17 |
Jiangsu Hengrui Medicine Co., Ltd. |
Anti-abeta antibody, antigen-binding fragment thereof and application thereof
|
|
WO2020072357A1
(en)
|
2018-10-04 |
2020-04-09 |
University Of Rochester |
Improvement of glymphatic delivery by manipulating plasma osmolarity
|
|
TW202035442A
(zh)
|
2018-12-20 |
2020-10-01 |
美商建南德克公司 |
經修飾之抗體Fc及其使用方法
|
|
CN112480253B
(zh)
|
2019-09-12 |
2022-09-20 |
普米斯生物技术(珠海)有限公司 |
一种抗pd-l1纳米抗体及其衍生物和用途
|
|
WO2021159024A1
(en)
|
2020-02-05 |
2021-08-12 |
Larimar Therapeutics, Inc. |
Tat peptide binding proteins and uses thereof
|
|
CN114106190B
(zh)
|
2020-08-31 |
2025-04-08 |
普米斯生物技术(珠海)有限公司 |
一种抗vegf/pd-l1双特异性抗体及其用途
|
|
CA3198456A1
(en)
|
2020-10-14 |
2022-04-21 |
Five Prime Therapeutics, Inc. |
Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
|
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
|
EP4297868A4
(en)
|
2021-02-23 |
2025-01-08 |
Hoth Therapeutics, Inc. |
USE OF APREPITANT TO TREAT ALZHEIMER'S
|
|
EP4410839A4
(en)
|
2021-09-30 |
2025-10-08 |
Bio Thera Solutions Ltd |
ANTI-B7-H3 ANTIBODY AND ITS USE
|
|
DK4186529T3
(da)
|
2021-11-25 |
2025-08-25 |
Veraxa Biotech Gmbh |
Forbedrede antistof-payload-konjugater (apc) fremstillet ved stedspecifik konjugering ved hjælp af genetisk kodeudvidelse
|
|
CA3238627A1
(en)
|
2021-11-25 |
2023-06-01 |
Christine Kohler |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
|
JP2024547111A
(ja)
|
2021-12-24 |
2024-12-26 |
バイオ－テラ ソリュ－ションズ，エルティーディー． |
抗ＦＲα抗体及びその抗体薬物コンジュゲート並びに使用
|
|
CN120958025A
(zh)
|
2022-12-16 |
2025-11-14 |
费恩治疗有限公司 |
针对含cub结构域的蛋白1(cdcp1)的抗体及其用途
|
|
WO2025027529A1
(en)
|
2023-07-31 |
2025-02-06 |
Advesya |
Anti-il-1rap antibody drug conjugates and methods of use thereof
|
|
WO2025126157A1
(en)
|
2023-12-15 |
2025-06-19 |
Advesya |
Anti-il-1rap binding domains and antibody-drug conjugates thereof
|
|
WO2025145091A1
(en)
|
2023-12-29 |
2025-07-03 |
Pfizer Inc. |
Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases
|
|
WO2025250454A1
(en)
|
2024-05-28 |
2025-12-04 |
University Of Rochester |
Adeno-associated viruses evolved to specifically target human glial progenitor cells in vivo
|